Работы, цитирующие эту работу

Работ: 2

Работа: CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

1. CAR-T cell combination therapy: the next revolution in cancer treatment

   Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa +8

   Обзорная статьяCAR-T cell therapy researchCancer Cell International2022Цитирований: 2

   ABIABI:AkademIndex/openalex/2022.review-article.000004

2. Genetic engineering in oncology based on CRISPR-Cas9 technology

   D. Polatova, А. Yu. Madaminov, А. V. Savkin +1

   СтатьяCRISPR and Genetic EngineeringSiberian Journal of Oncology2024Цитирований: 0

   ABIABI:AkademIndex/openalex/2024.article.008036